WILMINGTON, DE — Incyte (Nasdaq: INCY) announced its expansion in Delaware with the acquisition of two buildings in downtown Wilmington. Located at 1100 North King Street and 1100 North French Street, these acquisitions mark the company’s fourth Delaware expansion since establishing operations in Alapocas in 2014.
The new facilities will house Incyte’s U.S.-based teams, enhancing collaboration and allowing for future growth. Hervé Hoppenot, Incyte’s Chief Executive Officer, expressed excitement about the expansion. “The new buildings will enable our U.S. commercial and medical affairs teams to return to Delaware, fostering closer collaboration and supporting future growth,” he said. Hoppenot also thanked state and local officials for their support.
Governor John Carney hailed Incyte’s move as significant for both Wilmington and Delaware. “Incyte is a Delaware success story,” he said. “This move not only means more jobs but also more opportunities for Incyte to contribute to the community and advance their impactful research.”
The new King Street building is slated to open in 2026 and will initially accommodate over 400 employees from Incyte’s U.S. Oncology and Dermatology teams, currently based in Chadds Ford, PA, and global corporate employees from the Augustine Cut-off campus. Research and Development and Technical Operations teams will remain at the Alapocas location. The North French Street building will support future expansions.
Wilmington Mayor Mike Purzycki welcomed Incyte warmly. “Incyte’s expansion is a tremendous boost to our city’s economy and business community,” he said. “Their presence underscores Wilmington’s legacy as a hub of corporate innovation and development.”
Incyte’s acquisition signifies its ongoing commitment to Delaware, promising more jobs, economic benefits, and continued contributions to global health solutions.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.